Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Ophthalmology
Published in: BMC Ophthalmology 1/2019

Open Access 01-12-2019 | Diabetic Retinopathy | Research article

Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China

Authors: Shulin Liu, Desai Wang, Fei Chen, Xuedong Zhang

Published in: BMC Ophthalmology | Issue 1/2019

Login to get access

Abstract

Purpose

To investigate the dynamic changes of hyperreflective foci (HF) in diabetic macular edema (DME) patients during the intravitreal Conbercept treatment in China.

Methods

DME Patients receiving intravitreal Conbercept (IVC) injections during the year 2016–2017 were retrospectively investigated. Thirteen patients (26 eyes) were recruited in this study. They received IVC once a month for 3 consecutive months. The number and location of HFs, the best-corrected visual acuity (BCVA) and central macular thickness (CMT) at each visit were analyzed and compared.

Results

After the first injection, BCVA (LogMAR) was increased from 0.75 ± 0.48 to 0.43 ± 0.24 (p < 0.05), CMT improved from 575.9 ± 191.9 to 388.2 ± 198.5 μm (p = 0.014). However, the BCVA and CMT had no statistical difference after the second and third injection as compared with those after the first injection respectively. The baseline number of HFs was 5.39 ± 4.24, 5.15 ± 5.17 and 0.88 ± 1.90 in the inner retinal, outer retinal and subretinal layer respectively. The number of HFs in these three retinal layers decreased significantly after the first injection (p = 0.0045, p < 0.0001 and p = 0.0045, respectively). However, after the second injection, only the number of HFs in the inner retinal layer experienced a further decrease. After the third injection, no statistically significant HFs changes was observed in each retinal layers. Correlation analysis showed that there was a positive significant correlation between the baseline number of HFs in the inner retina, outer retina, subretina and final BCVA (r = 0.571, p = 0.002; r = 0.464, p = 0.017; r = 0.405, p = 0.04 respectively). There was also a significant positive correlation between outer retinal HFs reduction, total retinal HFs reduction and increase of BCVA (r = 0.40, p = 0.043 and r = 0.393, p = 0.04 respectively).
There were no severe ocular adverse reactions or systemic adverse events.

Conclusions

Conbercept is effective and safe in the treatment of DME. HFs can act as a biomarker of poor final visual outcome.
Literature
1.
Das A, McGuire P, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–94.CrossRef
2.
Stewart M. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014;14(8):510.CrossRef
3.
Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2009;26(1):204–10.CrossRef
4.
Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121(9):1740–7.CrossRef
5.
Huang Z, Ding Q, Yan M, Lian H, Chen Z, Chen X, Song Y. Short-term efficacy of CONBERCEPT and RANIBIZUMAB for POLYPOIDAL choroidal vasculopathy. Philadelphia, Pa: Retina; 2018.
6.
Jin E, Yin H, Li X, Zhao M. Short-term outcomes after intravitreal injections of CONBERCEPT versus RANIBIZUMAB for the treatment of retinopathy of prematurity. Philadelphia, Pa: Retina; 2017.
7.
Peng Y, Zhang X, Mi L, Liu B, Zuo C, Li M, Wen F. Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy. BMC Ophthalmol. 2017;17(1):87.CrossRef
8.
Li F, Sun M, Guo J, Ma A, Zhao B. Comparison of Conbercept with Ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Curr Eye Res. 2017;42(8):1174–8.CrossRef
9.
Li F, Zhang L, Wang Y, Xu W, Jiao W, Ma A, Zhao B. One-year outcome of Conbercept therapy for diabetic macular edema. Curr Eye Res. 2018;43(2):218–23.CrossRef
10.
Xu Y, Qu Y, Suo Y, Gao J, Chen X, Liu K, Xu X. Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment. BMC Ophthalmol. 2019;19(1):123.CrossRef
11.
Xu Y, Rong A, Xu W, Niu Y, Wang Z. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. BMC Ophthalmol. 2017;17(1):158.CrossRef
12.
Lee H, Lee J, Chung H, Kim HC. Baseline spectral domain optical coherence tomographic HYPERREFLECTIVE foci as a predictor of visual outcome and recurrence for central serous CHORIORETINOPATHY. Retina. 2016;36(7):1372–80.CrossRef
13.
Nishijima K, Murakami T, Hirashima T, Uji A, Akagi T, Horii T, Ueda-Arakawa N, Muraoka Y, Yoshimura N. Hyperreflective foci in outer retina predictive of photoreceptor damage and poor vision after vitrectomy for diabetic macular edema. Retina. 2014;34(4):732–40.CrossRef
14.
Chatziralli IP, Sergentanis TN, Sivaprasad S. HYPERREFLECTIVE foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or RANIBIZUMAB. Retina. 2016;36(12):2319–28.CrossRef
15.
De Benedetto U, Sacconi R, Pierro L, Lattanzio R, Bandello F. Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina. 2015;35(3):449–53.CrossRef
16.
Nagasaka Y, Ito Y, Ueno S, Terasaki H. Number of Hyperreflective Foci in the Outer Retina Correlates with Inflammation and Photoreceptor Degeneration in Retinitis Pigmentosa. Ophthalmol Retina. 2018;2(7):726-34.
17.
Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53(9):5814–8.CrossRef
18.
Mo B, Zhou HY, Jiao X, Zhang F. Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion. Int J Ophthalmol. 2017;10(4):605–12.PubMedPubMedCentral
19.
Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116(5):914–20.CrossRef
20.
Chen KC, Jung JJ, Curcio CA, Balaratnasingam C, Gallego-Pinazo R, Dolz-Marco R, Freund KB, Yannuzzi LA. Intraretinal Hyperreflective foci in acquired Vitelliform lesions of the macula: clinical and histologic study. Am J Ophthalmol. 2016;164:89–98.CrossRef
21.
Christenbury JG, Folgar FA, O'Connell RV, Chiu SJ, Farsiu S, Toth CA. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013;120(5):1038–45.CrossRef
22.
Coscas G, De Benedetto U, Coscas F, Li Calzi CI, Vismara S, Roudot-Thoraval F, Bandello F, Souied E. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde. 2013;229(1):32–7.CrossRef
23.
Kuroda M, Hirami Y, Hata M, Mandai M, Takahashi M, Kurimoto Y. Intraretinal hyperreflective foci on spectral-domain optical coherence tomographic images of patients with retinitis pigmentosa. Clin Ophthalmol (Auckland, NZ). 2014;8:435–40.CrossRef
24.
Ogino K, Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, Yoshimura N. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012;32(1):77–85.CrossRef
25.
Piri N, Nesmith BL, Schaal S. Choroidal hyperreflective foci in Stargardt disease shown by spectral-domain optical coherence tomography imaging: correlation with disease severity. JAMA Ophthalmol. 2015;133(4):398–405.CrossRef
26.
Murakami T, Yoshimura N. Structural changes in individual retinal layers in diabetic macular edema. J Diabetes Res. 2013;2013:920713.CrossRef
27.
Vujosevic S, Bini S, Midena G, Berton M, Pilotto E, Midena E. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. J Diabetes Res. 2013;2013:491835.PubMedPubMedCentral
28.
Uji A, Murakami T, Nishijima K, Akagi T, Horii T, Arakawa N, Muraoka Y, Ellabban AA, Yoshimura N. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153(4):710–7 717.e711.CrossRef
29.
Ehrlich R, Harris A, Ciulla T, Kheradiya N, Winston D, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88(3):279–91.CrossRef
30.
Kang JW, Lee H, Chung H, Kim HC. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1413–21.CrossRef
31.
Huang J, Li X, Li M, Li S, Xiao W, Chen X, Cai M, Wu Q, Luo D, Tang S, et al. Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012;14(7):644–53.CrossRef
32.
Ota M, Nishijima K, Sakamoto A, Murakami T, Takayama K, Horii T, Yoshimura N. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology. 2010;117(10):1996–2002.CrossRef
Metadata
Title
Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China
Authors
Shulin Liu
Desai Wang
Fei Chen
Xuedong Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2019
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-019-1168-0

Other articles of this Issue 1/2019

BMC Ophthalmology 1/2019 Go to the issue

Case report

Carotid-cavernous fistula(CCF) presenting as paroxysmal painful ophthalmoplegia

Research article

Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment

Study protocol

Visual impairment in children with a brain tumor: a prospective nationwide multicenter study using standard visual testing and optical coherence tomography (CCISS study)

Research article

Performance of femtosecond laser-assisted cataract surgery in Chinese patients with cataract: a prospective, multicenter, registry study

Case report

Increased thickness and decreased blood flow velocity of the choroid in a patient with acute macular neuroretinopathy

Research article

Protective effects of hydrogen gas in a rat model of branch retinal vein occlusion via decreasing VEGF-α expression